EJPMR, 2025, 12(11), 01-07 **Review Article** **Impact Factor 7.065**

EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

ISSN (O): 2394-3211
ISSN (P): 3051-2573
Coden USA: EJPMAG

HARENSSING ARTIFICIAL INTELLIGENCE & MACHINE LEARNING IN PHARMACEUTICAL QUALITY ASSURANCE

***Krushna Thorat**

India.

***Corresponding Author: Krushna Thorat**

India.

DOI: https://doi.org/10.5281/zenodo.17471509

How to cite this Article: Krushna Thorat. (2025). Harenssing Artificial Intelligence & Machine Learning in Pharmaceutical Quality Assurance. European Journal of Pharmaceutical and Medical Research, 12(11), 01–07.

Article Received on 23/09/2025 **Article Revised on 13/10/2025** **Article Published on 01/11/2025**

ABSTRACT

Artificial Intelligence (AI) has the disruptive potential to transform patients' lives via innovations in pharmaceutical sciences, drug development, clinical trials, and manufacturing. The pharmaceutical industry must maintain stringent quality assurance standards to ensure product safety and regulatory compliance. artificial intelligence and machine learning is revolution in pharmaceutical quality assurance. Artificial Intelligence can offers real-time monitoring of critical quality attributes and allowing prompt remedial actions in process and documentation. It also has a power to tools and automated documentation improve data integrity and expedite regulatory standard compliance. Machine learning algorithms are used in predictive maintenance and process optimization to reduce equipment downtime and guarantee constant production quality. This technique use to improve pharmaceutical quality standard, productivity, accuracy and regulatory compliance. In pharmaceutical industry, traditional procedure has a multiple significant problems including regulatory standard, timeline, and human error. This review paper covers innovative use of machine learning (ML) and artificial intelligence to enhance quality assurance and documentation in n the pharmaceutical industry.

KEYWORDS: Artificial Intelligence (AI), Machine learning (ML), Drug development, pharmaceutical.

INTRODUCTION

In recent years, the term "Artificial Intelligence" (AI) has become a household word for every one. Artificial intelligence (AI) are rapidly transforming numerous industries, like information technology, Automobiles, Biotechnology, food technology and processing also including pharmaceuticals, by offering advanced techniques for data analysis and decision-making.[1] Artificial intelligence (AI) has potentials to ensure product safety, efficacy, and Compliance with regulatory standard.[2] Since it offers a systematic approach to defect reduction and process improvement. The term "AI" is a diverse set of inquiries and development from various disciplines and conceptual strategies with no universally accepted definition, often seen as research that creates technologies capable of tasks requiring human-like intelligence.[3] Artificial intelligence (AI) was first introduced in a workshop proposal in 1950, driven by neuro-robotic and brain mechanisms envisioned for tomography image analysis.[4] In the 1980s, Fletcher and Doi at the University of Chicago suggested the potential applicability of AI/machine learning (AI/ML) in the medical field for the first time.[5]

Machine learning (ML), specifically focuses on developing algorithms that learn from data to make predictions without explicit programming.[6] Within ML, deep learning (DL) stands out as a sub-field utilizing artificial neural networks (ANNs), which mimic the human brain's structure to identify complex patterns and relationships in large datasets.[7] These technologies have achieved cutting-edge results in domains like image identification natural language understanding, and speech detection.[8]

which has improved efficiency, accuracy, and compliance. While machine learning (ML), a subset of artificial intelligence (AI), uses statistical models and

algorithms to help computers learn from data and make decisions, AI itself refers to the emulation of human intelligence by computer systems.[9] Numerous uses of these technologies, including supply chain management, real-time monitoring, data integrity, predictive analytics, and improved analytical procedures, have been found in pharmaceutical quality control.[10]

The potential of Artificial Intelligence (AI) as far as applicability in the field of healthcare is concerned is tremendous. Administrative and operating systems, entrenched in Artificial Intelligence, would in time be capable of not just handling routine and procedural tasks, but also of handling complex and high-pressure situations optimally.[11] Drug development is a lengthy, complex, and costly process marked by extensive clinical trials, substantial risks, and stringent regulations. Artificial intelligence (AI) has the potential to transform the entire drug development process—from accelerating drug discovery and optimizing clinical trials to improving manufacturing and supply chain logistics.[12]

Advantages and Challenges of Artificial Intelligence & machine learning in pharmaceutical quality assurance

The incorporation of Artificial Intelligence (AI) and Machine Learning (ML) into quality assurance and documentation processes in the pharmaceutical industry presents a variety of advantages and obstacles that influence the process and results.[13] Pharmaceutical industry expect that to successfully improve quality assurance methods via the use of new technology must comprehend these elements.[14]

Advantages

Increased data correctness and integrity: Automated data collection, analysis, and validation are made possible by AI and ML technologies, which reduce mistakes and guarantee the quality of documentation.[15] Pharmaceutical firms may improve decision-making and product quality by improving crucial quality measures' correctness and integrity via the elimination of manual data input methods.[16]

• Improved productivity and less manual labour

Using AI and ML to automate documentation processes simplifies workflows, cuts down on human labour, and quickens the documentation process. Employees may now concentrate on higher-value tasks by doing tasks like data entry, analysis, and reporting more effectively. These tasks used to demand a lot of time and resources.[17]

• Improved adherence to regulatory standards

In the pharmaceutical sector, where strict laws control all facets of medication discovery, production, and distribution, adherence to regulatory standards is of utmost importance.[18] By offering automated validation checks, real-time monitoring, and predictive analytics to foresee and proactively resolve any compliance concerns, AI and ML technologies help businesses ensure compliance.[19]

• Predictive analytics for proactive quality management

Using predictive analytics for proactive quality management is one of the biggest advantages of incorporating AI and ML into Six Sigma documentation.[20] By identifying patterns and trends in past data, machine learning algorithms allow for the predictive modelling of potential quality problems in the future. Pharmaceutical firms can prevent risks, guarantee product consistency, and protect patient safety by foreseeing probable deviations or flaws in advance.[21]

Challenges

Data transfer, workflow redesign, and compatibility with legacy systems are all necessary for the successful integration of AI and ML technologies into current documentation systems and procedures. Achieving a successful installation requires ensuring a smooth interface with the current infrastructure while minimising any disturbance to ongoing activities.

• Initial expenses and resource commitment

Putting AI and ML technologies into practice comes with a hefty upfront cost that includes spending on staff training, software, and hardware. To get funds for implementation, pharmaceutical firms need to strategically deploy resources and demonstrate to stakeholders the return on investment (ROI).[22]

• Requirement for qualified staff

Effective use of AI and ML requires specific knowledge in software development, data science, and machine learning. Pharmacies may have trouble finding and keeping qualified employees who have the technical know-how and domain expertise needed to deploy and manage AI/ML systems.[23]

• Data security and privacy issues

When handling sensitive patient data and proprietary data, using AI and ML technologies presents issues with data security, privacy, and regulatory compliance. To guard against unauthorised access, breaches, and data abuse, pharmaceutical businesses need to put strong data governance rules, encryption mechanisms, and access controls into place.[24]

Developments in ML and AI

Pharmaceutical quality assurance has a great deal of potential in light of emerging trends and developments in AI and ML.

• Deep Learning Advancements

With the fast advancement of deep learning methods, including convolutional neural networks (CNNs) and recurrent neural networks (RNNs), more precise analysis of complicated pharmacological datasets is now possible. By making it easier to identify minute patterns,

irregularities, and correlations in manufacturing processes, these strategies enhance quality control and help eliminate defects.[25]

• Explainable AI

Explainable AI is becoming more and more popular as a vital aspect of pharmaceutical quality control, especially in terms of decision making and regulatory compliance. Explainable AI improves accountability, transparency, and trust by offering interpretable insights into AI-driven forecasts and recommendations. This makes it possible for stakeholders to successfully comprehend and evaluate AI-generated outputs.[26]

• Real-time Monitoring and Predictive Analytics

Predictive analytics and real-time monitoring are now possible in pharmaceutical production thanks to AI and ML technologies, which also enable proactive quality problem diagnosis and remediation. AI-driven models may anticipate equipment failures, process deviations, and product defects by evaluating past production records and streaming sensor data. This allows for prompt interventions and continual process improvement.[27]

• Automated Quality Control

Pharmaceutical manufacturing lines are using AI, ML algorithms more, and more for automated quality control. Artificial intelligence (AI)-powered computer vision systems can more accurately and efficiently check pharmaceutical items for flaws like chips, fractures, or discolorations than human inspectors can. These technologies save waste, increase product quality, and lower the possibility of product recalls.[28]

AI and ML Integration in Documentation

The use of artificial intelligence (AI) and machine learning (ML) technology in documentation presents opportunities for improving productivity, accuracy, and overall quality control. Predictive analytics, real-time monitoring and reporting, improving data quality and integrity, automating data collection, and incorporating AI and ML into documentation processes are all covered in this area.

1 Automating the Gathering of Data

Technologies like AI and ML have the power to completely change how Six Sigma initiatives gather data. Data collecting in the past required human input, which was laborious and prone to mistakes. Data acquisition may be accelerated and human involvement reduced by using AI and ML to automate data collecting operations.[29] AI-powered systems, for instance, may remove the need for human input by extracting data from a variety of sources, including databases, sensors, and digital records. Machine learning algorithms have the ability to use past data trends to forecast future data needs, hence streamlining data collecting tactics and guaranteeing thorough coverage of pertinent variables. Pharmaceutical businesses may increase the overall effectiveness of Six Sigma programmes, minimise mistakes, and simplify documentation procedures by automating data collecting.[30]

2 Improving the Integrity and Accuracy of Data

Since choices and actions in Six Sigma documentation are based on the insights gained from this data, it is crucial to ensure the quality and integrity of the data. AI and ML provide sophisticated ways to improve data integrity and accuracy by using algorithms to identify and fix mistakes instantly.[31] For example, machine learning algorithms are capable of spotting outliers or abnormalities in datasets and marking them for more research or adjustment. The accuracy of documentation may be ensured by using Natural Language Processing (NLP) tools to examine textual material for inconsistencies or errors. Furthermore, AI-driven validation tests may confirm data quality throughout the documentation process by comparing data integrity to predetermined criteria. AI and ML support Six Sigma documentation's credibility and dependability by improving data correctness and integrity, which increases trust in decision-making and quality improvement initiatives.[32]

3 Analytics for Predictive

Utilising AI and ML to integrate predictive analytics for proactive quality control is one of the main advantages of Six Sigma documentation. By using machine learning algorithms to examine past data and find patterns and trends, future quality problems may be predicted. Pharmaceutical businesses may reduce risks and address underlying causes by anticipating deviations or flaws and taking preventive action. Predictive maintenance models provide the ability to foresee equipment problems by analysing use patterns. This allows for the urging of repair actions to avoid quality deviations or production downtime. Predictive analytics can also foresee problems with regulatory compliance or supply chain interruptions, enabling proactive management and mitigation techniques. Pharmaceutical firms may increase their capacity to foresee and address quality issues, leading to continuous improvement and operational excellence, by using predictive analytics.[33]

4 Monitoring and Reporting in Real Time

Real-time quality metrics monitoring and reporting are made possible by AI-driven systems, giving stakeholders rapid information on process performance and deviations. Pharmaceutical firms may continually monitor key process parameters and quality indicators by integrating sensors, IoT devices, and AI algorithms. When certain thresholds are exceeded, warnings or messages are sent out, requiring quick remedial action. Moreover, AI-driven dashboards and reporting tools provide stakeholders clear visual representations of important performance indicators, promoting transparency and data-driven decision-making across the company. Pharmaceutical businesses may minimise the effect on patient safety and product quality by rapidly

identifying and addressing quality concerns via real-time monitoring and reporting.[34]

Real-Time Monitoring and Quality Assurance

Process Analytical Technology (PAT)

Process Analytical Technology (PAT) is a system that uses real-time measurements of critical quality attributes (CQAs) to develop, analyze, and regulate pharmaceutical production processes. Wasalathanthri real-time CQA monitoring is made possible by AI-driven PAT tools, guaranteeing that the manufacturing process stays within predetermined bounds. AI and ML improve PAT because they offer sophisticated data analysis tools. For example, PAT frequently uses spectroscopy to track CQAs. Machine learning algorithms can analyze real-time spectrophotometric data to identify deviations from the intended quality standards. Consistent product quality can be ensured by making quick adjustments to the manufacturing process based on this real-time feedback.[35]

Anomaly Detection

Anomaly detection is another crucial use of AI and ML in pharmaceutical quality control. ML algorithms can predict possible quality concerns before they become more severe by detecting deviations from regular production processes. Models for detecting anomalies use data from various sensors and devices to find trends that point to unusual activity. For instance, machine learning algorithms can keep an eye on variables like pH, temperature, and oxygen concentrations in bioreactors during the production of biopharmaceuticals. The models can identify deviations in these parameters, which can notify operators about possible problems and facilitate timely corrections.[36]

Data Integrity and Compliance

Automated Documentation

In pharmaceutical manufacturing, data integrity is a basic need that guarantees the accuracy, consistency, and dependability of all data about the manufacture and quality control of pharmaceuticals. By automating the documentation process, AI technologies can improve data integrity and lower the possibility of human error. Automated documentation systems use artificial intelligence (AI) to collect and store data from various sources, including manual input, production equipment, and lab instruments. These solutions guarantee that all information is correctly captured and kept in a legally compliant way. AI, for instance, can be used to automate the recording of quality control test results, guaranteeing that all relevant information is recorded and kept in an electronic manner that conforms to legal specifications.[37]

Audit Readiness

A crucial part of producing pharmaceuticals is conducting regulatory audits to meet other regulatory requirements, such as Good Manufacturing Practices (GMP). By arranging and evaluating vast amounts of data, artificial intelligence (AI) can expedite the audit process and simplify proving compliance to regulatory agencies.[38]

AI-powered audit preparedness technologies can detect compliance problems by analyzing data from various sources, including equipment logs, batch records, and QC test results. These technologies can also provide audit reports, which thoroughly summarise the compliance situation and point out areas that need attention. Artificial intelligence lessens the workload for quality assurance teams and guarantees that businesses are always ready for regulatory audits by automating these operations.[39]

Enhanced Analytical Techniques

Spectroscopy and Imaging

In pharmaceutical quality control, spectroscopy and imaging are crucial methods for examining substances' physical and chemical makeup. By offering sophisticated data analysis skills, ML improves the detection of contaminants and guarantees the consistency of pharmaceutical products, hence augmenting these procedures.[40] ML algorithms, for instance, can evaluate spectral data from near infrared (NIR) spectroscopy to locate and measure APIs and excipients in a drug formulation. These algorithms can identify minute alterations in spectral patterns that could indicate contaminants or compositional changes. Similar to this, machine learning (ML) can be used to interpret imaging data from methods like mass spectrometry and high-performance liquid chromatography (HPLC), yielding more accurate and trustworthy results.[41]

Chemometrics

Chemometrics studies chemical data analysis using statistical and mathematical techniques. Complex chemical data can be analyzed using AI-based chemometric models, which makes it easier to create reliable QC procedures. By recognizing patterns and correlations in chemical data, these models make it possible to forecast quality attributes based on the characteristics of raw materials and process variables.

For instance, ML algorithms can analyze HPLC data to determine whether a pharmaceutical formulation has contaminants. Chemometric models can provide realtime product quality forecasts by constructing predictive models based on past data, allowing for proactive QC actions.[42]

FUTURE PROSPECTS

There is much promise for using AI and ML in pharmaceutical quality control. Further improvements in QC procedures are anticipated because of developments in AI technologies like deep learning and natural language processing. By enabling proactive quality control procedures and lowering the likelihood of quality problems, these technologies can produce more accurate and dependable predictions. Cooperation between

technology businesses, pharmaceutical companies, and regulatory agencies will be crucial to fully utilizing AI and ML. Together, these parties can create best practices and recommendations for applying AI and ML in pharmaceutical quality control, ensuring these tools are used sensibly and successfully.

To identify potential quality issues and optimize production processes, deep learning systems, for instance, may examine complicated data from numerous sources, including genomic data, clinical trial results, and real-world evidence. Research articles and regulatory documents are examples of unstructured data that can be analyzed using natural language processing to provide essential insights for quality control procedures. Moreover, pharmaceutical quality control may gain even more advantages from combining AI and ML with cutting-edge technologies like blockchain and the Internet of Things. Blockchain technology can guarantee the integrity and transparency of data throughout the supply chain, while IoT sensors can offer real-time data on environmental conditions and manufacturing operations.

CONCLUSION

Pharmaceutical quality control is changing due to AI and ML, which provide notable gains in productivity, precision, and regulatory compliance. Using these technologies, pharmaceutical firms can improve supply chain management, data integrity, predictive analytics, real-time monitoring, and analytical approaches. The potential benefits of AI and ML are significant, even though issues remain resolved, including data quality, regulatory compliance, integration, and ethical considerations. We anticipate a future where QC processes are more resilient, dependable, and capable of guaranteeing the highest standards of product quality and patient safety as the pharmaceutical sector embraces AI and ML. Cooperation amongst technology suppliers, pharmaceutical companies, and regulatory agencies will be crucial to fully realize this potential and guarantee the ethical and efficient application of AI and ML in pharmaceutical quality control.

REFERENCE

1. Sharma, Saurabh, Vijay Kumar Gahlawat, Kumar Rahul, Rahul S. Mor, and Mohit Malik. "Sustainable innovations in the food industry through artificial intelligence and big data analytics." Logistics 5, no. 4 (2021): 66.
2. Malik, Shiza, Khalid Muhammad, and Yasir Waheed. "Artificial intelligence and industrial applications-A revolution in modern industries." Ain Shams Engineering Journal, 2024; 15(9): 102886.
3. Panagiotopoulos, Nikolaos. "Capabilities of Engineers to Build Machines with Human-like Intelligence Using Artificial Intelligence (AI) and Machine Learning (ML)." Recent Research Advances in Arts and Social Studies 2024; 9: 45-73.
4. Mirakhori, Fahimeh, and Sarfaraz K. Niazi. "Harnessing the AI/ML in drug and biological products discovery and development: the regulatory perspective." Pharmaceuticals, 2025; 18(1): 47.
5. El Hajj, Mohammad, and Jamil Hammoud. "Unveiling the influence of artificial intelligence and machine learning on financial markets: A comprehensive analysis of AI applications in trading, risk management, and financial operations." Journal of Risk and Financial Management, 2023; 16(10): 434.
6. Sarker, Iqbal H. "Machine learning: Algorithms, real-world applications and research directions." SN computer science, 2021; 2(3): 160.
7. Sravani, Kambham, and Kuppusamy Pothanaicker. "Comprehensive Autism Spectrum Disorder Analysis: ML and DL Models in Multimodal Datasets." Ingenierie des Systemes d'Information, 2024; 29(6): 2467.
8. Solomon, Dahlak Daniel, Karan Kumar, Kushal Kanwar, Sailesh Iyer, and Manoj Kumar. "Extensive Review on the Role of Machine Learning for Multifactorial Genetic Disorders Prediction." Archives of Computational Methods in Engineering, 2024; 31(2).
9. Duan, Yanqing, John S. Edwards, and Yogesh K. Dwivedi. "Artificial intelligence for decision making in the era of Big Data–evolution, challenges and research agenda." International journal of information management, 2024; 48: 63-71.
10. Leal, Fátima, Adriana E. Chis, Simon Caton, Horacio González–Vélez, Juan M. García–Gómez, Marta Durá, Angel Sánchez–García et al. "Smart pharmaceutical manufacturing: Ensuring end-to-end traceability and data integrity in medicine production." Big Data Research, 2021; 24: 100172.
11. Purohit, Naresh, and Varsha Narayanan. "Harnessing the Potential of Artificial Intelligence and Machine Learning Technologies in Building the Future of Healthcare Services." The Indian Practitioner, 2024; 77(2): 6-8.
12. Ogbuagu, Oluchukwu Obinna, Akachukwu Obianuju Mbata, Obe Destiny Balogun, Olajumoke Oladapo, Opeyemi Olaoluawa Ojo, and Muridzo Muonde. "Optimizing supply chain logistics for personalized medicine: Strengthening drug discovery, production, and distribution." International Journal of Multidisciplinary Research and Growth Evaluation, 2023; 4(3): 832-841.
13. Singh, Shubham. "Leveraging AI and Machine Learning in Six- Sigma Documentation for Pharmaceutical Quality Assurance." Chinese Journal of Applied Physiology, 2024; 40: e20240005.
14. Kabir, Mohosin, Md Refayet Hossen Rana, and Arnab Debnath. "The Role of Quality Assurance in Accelerating Pharmaceutical Research and Development: Strategies for Ensuring Regulatory Compliance and Product Integrity." Integrative Biomedical Research, 2024; 8(12): 1-11.

15. Singh, Shubham. "Leveraging AI and Machine Learning in Six- Sigma Documentation for Pharmaceutical Quality Assurance." Chinese Journal of Applied Physiology, 2024; 40: e20240005.
16. Saha, Gonesh Chandra, Lima Nasrin Eni, Hasi Saha, Prasanta Kumar Parida, Ravichandaran Rathinavelu, Sanjiv Kumar Jain, and Barun Haldar. "Artificial intelligence in pharmaceutical Manufacturing: Enhancing quality control and decision making." Rivista Italiana di Filosofia Analitica Junior, 2023; 14(2).
17. Dobariya, Parina, M. Chandrakantbhai Vaghela, and P. Bhagwan Deshpande. "Harnessing artificial intelligence and machine learning in six- sigma documentation for pharmaceutical quality assurance." J Chem Heal Risks, 2024; 14(3) 2753-2766.
18. Petrova, Elina. "Innovation in the pharmaceutical industry: The process of drug discovery and development." In Innovation and marketing in the pharmaceutical industry: emerging practices, research, and policies, pp. 19-81. New York, NY: Springer New York, 2013.
19. Odetunde, Azeez, Bolaji Iyanu Adekunle, and Jeffrey Chidera Ogeawuchi. "Using Predictive Analytics and Automation Tools for Real-Time Regulatory Reporting and Compliance Monitoring." Int. J. Multidiscip. Res. Growth Eval, 2022; 2(3): 650-661.
20. Gonzalez Santacruz, Elisa, David Romero, Julieta Noguez, and Thorsten Wuest. "Integrated quality 4.0 framework for quality improvement based on Six Sigma and machine learning techniques towards zero-defect manufacturing." The TQM Journal, 2025: 37(4): 1115-1155.
21. Ahmed, Rashed. "Ensuring Quality Medicine is not a Single Event but Rather Combines Effects of a Pharmaceutical Company." Radinka Journal of Health Science, 2024; 2(2): 226-241.
22. Dhayanidhi, Glory. "Research on IoT threats & implementation of AI/ML to address emerging cybersecurity issues in IoT with cloud computing." (2022).
23. Alvarez- Rodríguez, Jose María, Roy Mendieta Zuñiga, Valentín Moreno Pelayo, and Juan Llorens. "Challenges and opportunities in the integration of the Systems Engineering process and the AI/ML model lifecycle." In INCOSE International Symposium, 2019; 29(1): 560-575.
24. Maguluri, Kiran Kumar, V. K. A. T. Ganti, and Tulasi Naga Subhash. "Advancing Patient Privacy in the Era of Artificial Intelligence: A Deep Learning Approach to Ensuring Compliance with HIPAA and Addressing Ethical Challenges in Healthcare Data Security." International Journal of Medical Toxicology & Legal Medicine, 2025; 27(5).
25. Dhafr, Nasreddin, Munir Ahmad, Brian Burgess, and Siva Canagassababady. "Improvement of quality performance in manufacturing organizations by minimization of production defects." Robotics and Computer-Integrated Manufacturing, 2025; 22(5-6): 536-542.
26. Belghachi, Mohammed. "A review on explainable artificial intelligence methods, applications, and challenges." Indonesian Journal of Electrical Engineering and Informatics (IJEEI), 2023; 11(4): 1007-1024.
27. Rajesh, Mukesh Vijayarangam, and Karthikeyan Elumalai. "The transformative power of artificial intelligence in pharmaceutical manufacturing: Enhancing efficiency, product quality, and safety." Journal of Holistic Integrative Pharmacy, 2025; 6(2): 125-135.
28. Saha, Gonesh Chandra, Lima Nasrin Eni, Hasi Saha, Prasanta Kumar Parida, Ravichandaran Rathinavelu, Sanjiv Kumar Jain, and Barun Haldar. "Artificial intelligence in pharmaceutical Manufacturing: Enhancing quality control and decision making." Rivista Italiana di Filosofia Analitica Junior, 2023; 14(3).
29. Bukhari, Syed Muhammad Shakir, and Rehman Akhtar. "Leveraging Artificial Intelligence To Revolutionize Six Sigma: Enhancing Process Optimization And Predictive Quality Control." Contemporary Journal of Social Science Review 2024; 2(04): 1932-1948.
30. Singh, Shubham. "Leveraging AI and Machine Learning in Six- Sigma Documentation for Pharmaceutical Quality Assurance." Chinese Journal of Applied Physiology, 2024; 40: e20240005.
31. Panwar, Vijay. "AI-Powered Data Cleansing: Innovative Approaches for Ensuring Database Integrity and Accuracy." International Journal of Computer Trends and Technology, 2024; 72(4): 116-122.
32. Bukhari, Syed Muhammad Shakir, and Rehman Akhtar. "Leveraging Artificial Intelligence To Revolutionize Six Sigma: Enhancing Process Optimization And Predictive Quality Control." Contemporary Journal of Social Science Review, 2024; 2(4): 1932-1948.
33. Çınar, Zeki Murat, Abubakar Abdussalam Nuhu, Qasim Zeeshan, Orhan Korhan, Mohammed Asmael, and Babak Safaei. "Machine learning in predictive maintenance towards sustainable smart manufacturing in industry 4.0." Sustainability, 2020; 12(19): 8211.
34. Artene, Alin Emanuel, Aura Emanuela Domil, and Larisa Ivascu. "Unlocking Business Value: Integrating AI-Driven Decision-Making in Financial Reporting Systems." Electronics, 2024; 13(15): (2079-9292).
35. Yang, Feng, Jennifer Zhang, Alexander Buettner, Eva Vosika, Monica Sadek, Zhiqi Hao, Dietmar Reusch et al. "Mass spectrometry-based multi-attribute method in protein therapeutics product quality monitoring and quality control." In MAbs, 15(1): 2197668. Taylor & Francis, 2023.
36. Hill, David J., and Barbara S. Minsker. "Anomaly detection in streaming environmental sensor data: A

data-driven modeling approach." Environmental Modelling & Software, 2010; 25(9): 1014-1022.
37. Baviskar, Dipali, Swati Ahirrao, Vidyasagar Potdar, and Ketan Kotecha. "Efficient automated processing of the unstructured documents using artificial intelligence: A systematic literature review and future directions." Ieee Access, 2021; 9: 72894-72936.
38. Saha, Gonesh Chandra, Lima Nasrin Eni, Hasi Saha, Prasanta Kumar Parida, Ravichandaran Rathinavelu, Sanjiv Kumar Jain, and Barun Haldar. "Artificial intelligence in pharmaceutical Manufacturing: Enhancing quality control and decision making." Rivista Italiana di Filosofia Analitica Junior, 14(2): 2023.
39. Kandhare, Priyanka, Mrunal Kurlekar, Tanvi Deshpande, and Atmaram Pawar. "A review on revolutionizing healthcare technologies with AI and ML applications in pharmaceutical sciences." Drugs and Drug Candidates, 2025; 9: 4(1).
40. Kodumuru, Reshma, Soumavo Sarkar, Varun Parepally, and Jignesh Chandarana. "Artificial Intelligence and Internet of Things Integration in Pharmaceutical Manufacturing: A Smart Synergy." Pharmaceutics, 2025; 17(3): 290.
41. Gbashi, Sefater, and Patrick Berka Njobeh. "Enhancing food integrity through artificial intelligence and machine learning: a comprehensive review." Applied Sciences, 2024; 14(8): 3421.
42. Srivastava, Madhumita, Shiv Nandan, Aliza Zaidi, Arzoo Saifi Samani, Vijaya Shukla, Hasan Aslam, Anshumaan Srivastava et al. "Artificial Intelligence Driven Applications in Analytical Chemistry, Drug Discovery, and Food Science: Advancements, Outlook, and Challenges." Chemistry Select, 2025; 101(16): e202404446.